BRCA 1 & 2, ATM, CDH1, CHEK2, MRE11A, NBN, p53, PALB2, PTEN, RAD50, RECQL, and RINT1 genes
Posted on: Jun 15, 2017 03:58PM
Lynparza Better Than Standard Chemotherapy for HER2-Negative Metastatic Breast Cancer in Women With BRCA Mutations
June 15, 2017
A study found that Lynparza improved progression-free survival by about 3 months in women diagnosed with metastatic, HER2-negative breast cancer who had a BRCA1 or BRCA2 mutation. Read more...